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MANAGING THE MEDICAL MATRIX:
A “DAIS” FOR ARTIFICIAL INTELLIGENCE IN HEALTH
CARE (AND BEYOND)
Layla G. Maurer
AI offers “huge and wide-reaching potential” in health; the futures of health care
and AI are deeply interconnected. Use of AI provides the field with never-beforeimagined opportunities to streamline and delve more deeply into medical care,
including disease identification, diagnosing conditions, and a simpler way to
crowdsource and develop treatment plans. Its broad inclusion in the field has
created a pressing need for more, and better, regulation. Improved regulation is
especially critical because of the possibility that mismanaged AI will allow for
incorrect diagnosis of patients or biased predictions and outcomes. In fact,
numerous examples of such bias – and attempts to manage bias – already exist,
which raises major ethical questions surrounding the use of AI and presents the
issue of how to avoid health disparities in AI.
In this Note, I argue that AI is not being adequately managed at the federal level.
I further argue that the lack of management is largely due to a general failure to
mandate standards for data sourcing, cleaning, and testing. The health care field
is rife with examples of the effects of poor management, some of which have
immediate and devastating impacts on patients; however, mismanagement of AI is
not limited to health care alone. The potential problems that arise from lack of
oversight span across industry lines. Thus, no single industry or existing federal
agency can claim full ownership of, or expertise in, AI as a tool. I therefore
propose that the best possible solution would be to form an entirely new top-level
federal agency. This new agency would be tasked with creating federally
mandated standards for ethical AI data sourcing, cleaning, and testing across
industries. It would provide comprehensive management of AI datasets that do not
fall under the umbrella of an existing agency such as the Food & Drug
Administration (FDA). I further propose that the new regulatory body be named
the “Department of Artificial Intelligence Standardization,” or DAIS.
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I.

Introduction

In February 2011, the world watched in entertained awe as the 74-time
Jeopardy! winner Ken Jennings was unseated not by a human, but a machine. The
triumphant contestant was named, simply, “Watson.” Watson was a “question
answering machine”1 developed by IBM in 2010.2 In front of thousands of
viewers, Watson showcased its ability to process natural language and quickly
provide accurate responses3—in the form of a question, of course.4 Watson runs
over 100 algorithms after receiving a query.5 It uses those algorithms to analyze
questions, then finds evidence that may support or refute potential answers to the
initial query.6 In the Jeopardy! setting, Watson considered what degree of
confidence it had in its answer before choosing whether to “buzz in” and risk
losing money, further illustrating its quick-thinking capabilities.7 Watson was a
stunning display of the potential of language processing and automated
decision -making. On the heels of the Jeopardy! success, IBM quickly announced
Watson’s next step: applications of its algorithms to medical analysis.8
In 2014, IBM made a “moonshot” display of Watson’s ability to provide
potential patient diagnoses from a “bizarre collection” of patient symptoms.9
Hopes were high for the automated system.10 Disappointingly, subsequent Watson
projects have fallen short of creating a true “AI doctor.”11 For example, in 2018,
Watson stumbled significantly by recommending “unsafe and incorrect”
1

John Markoff, Computer Wins on ‘Jeopardy!’: Trivial, It’s Not, N.Y. TIMES (Feb. 16, 2011),
https://www.nytimes.com/2011/02/17/science/17jeopardy-watson.html.
2
IBM, A Computer Called Watson, IBM, https://www.ibm.com/ibm/history/ibm100/us/en/icons/
watson/ (last visited Apr. 19, 2022).
3
Markoff, supra note 1.
4
See Raman Chandrasekar, Elementary? Question Answering, IBM’s Watson, and the Jeopardy!
Challenge, 19 RESONANCE 222, 237–40 (2014) (discussing the rules of the Jeopardy! game
show that requires contestants to respond to prompts with questions. Watson was programmed to
respond in this manner for its appearances on the show.).
5
IBM, supra note 2.
6
Chandrasekar, supra note 4, at 236.
7
Id. at 234.
8
Markoff, supra note 1.
9
Eliza Strickland, How IBM Watson Overpromised and Underdelivered on AI Health Care, IEEE
SPECTRUM (Apr. 2, 2019), https://spectrum.ieee.org/biomedical/diagnostics/how-ibm-watsonoverpromised-and-underdelivered-on-ai-health-care.
10
See generally Adam Miller, The future of healthcare could be elementary with Watson, 185
CMAJ E367, E367–68 (2013) (discussing the advantage for oncologists of staying up to date on
research through Watson).
11
Id.
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treatments for cancer patients.12 Both IBM’s engineers and Watson’s initial
adopters, Memorial Sloan Kettering Cancer Center, were blamed for this
stumble;13 together they trained Watson on a limited set of hypothetical cancer
cases instead of real patient data and relied on limited treatment
recommendations, rather than evidence, in selecting treatment options.14
Despite its missteps and although it did not replace traditional diagnosis
methods,15 Watson is still a participant in medical artificial intelligence (“AI”).16
Watson is currently being used for research into the usability of electronic health
records (“EHR”) and support of “precision medicine,” which is “an emerging
approach for disease treatment and prevention that takes into account variability
in genes, environment, and lifestyle for each person.”17 Watson’s early successes
and experiments also paved the way for future developments in AI and natural
language processing (“NLP”) in health care.18
AI has gained significant attention in the context of improving health and
well-being.19 AI is exciting and trendy: news media is laden with stories about
noteworthy uses of algorithms, including health-related applications ranging from
12

Julie Spitzer, IBM’s Watson recommended ‘unsafe and incorrect’ cancer treatments, STAT
report finds, BECKER’S HEALTH IT (July 25,
2018), https://www.beckershospitalreview.com/artificial-intelligence/ibm-s-watsonrecommended-unsafe-and-incorrect-cancer-treatments-stat-report-finds.html
[https://perma.cc/T7ND-NTNF].
13
Id.
14
Id.
15
Strickland, supra note 9.
16
Although Watson is still operational in health care, IBM reportedly began exploring sale of IBM
Watson Health and its associated brands in February of 2021 due to its not currently being
profitable. See Laura Cooper & Cara Lombardo, IBM Explores Sale of IBM Watson Health, WALL
ST. J. (Feb. 18, 2021), https://www.wsj.com/articles/ibm-explores-sale-of-ibm-watson-health11613696770 [https://perma.cc/M4KM-PEDN]. As of the date of this writing, Watson Health has
not yet been sold. See id.
17
Jennifer Bresnick, IBM Watson Health Teams Up with Hospitals for AI, EHR Research,
HEALTH IT ANALYTICS (Feb. 20, 2019), https://healthitanalytics.com/news/ibm-watson-healthteams-up-with-hospitals-for-ai-ehr-research; What is precision medicine?, NAT. INST. HEALTH:
MEDLINEPLUS GENETICS,
https://medlineplus.gov/genetics/understanding/precisionmedicine/definition/ (last visited Jan. 26,
2021).
18
Ashish Kachru, Why Artificial Intelligence Hype In Health Care Isn’t A Bad Thing, FORBES (Oct.
2, 2019), https://www.forbes.com/sites/forbestechcouncil/2019/10/02/why-artificial-intelligencehype-in-health-care-isnt-a-bad-thing/ (discussing how, after IBM made its “moonshot” with AI in
health care, researchers have begun making incremental developments in health care AI including
prediction of risk for hospital admissions and identification of vulnerabilities in home-based
“medically fragile” patients).
19
Id. at 5.
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virtual fitness to COVID-19 vaccinations.20 This should be no surprise, as pop
culture has been preparing us for machine-based intelligence for most of our lives;
to see pop culture’s promises begin to come to fruition is inspiring.21 In the
Jeopardy! program from 2011, Ken Jennings himself referenced pop culture in his
final answer when he realized that Watson had won handily: he wrote “I, for one,
welcome our new computer overlords.”22 Early chatter about Watson naturally
compared it to the responsive computer system in the Star Trek universe.23
Needless to say, we are not yet at Star Trek levels of omnipresent AI, but we are
making vast strides towards more effective use of AI in health technology. The
industry is ready: the term “AI” is all the buzz in health care.24
Because AI offers “huge and wide-reaching potential”25 in health, the
futures of health care and AI are deeply interconnected.26 Use of AI provides the
field with never-before-imagined opportunities to streamline and delve more
deeply into medical care, including disease identification, diagnosing conditions,

20

See, e.g., CES 2021 Uniigym combines AI and cloud algorithms to change virtual fitness apps,
PR NEWSWIRE: CISION (Jan. 14, 2021), https://www.prnewswire.com/news-releases/ces-2021uniigym-combines-ai-and-cloud-algorithms-to-change-virtual-fitness-apps-301208290.html;
Siddharth Venkataramakrishnan, Algorithms and the coronavirus pandemic, FIN. TIMES (Jan. 10,
2021), https://www.ft.com/content/16f4ded0-e86b-4f77-8b05-67d555838941; Drew Harwell,
Algorithms are deciding who gets the first vaccines. Should we let them?, WASH. POST (Dec. 23,
2020), https://www.washingtonpost.com/technology/2020/12/23/covid-vaccine-algorithm-failure/.
21
See Frank Landman, Pop Culture and AI: How Media Is Reshaping Public
Perceptions, READWRITE (July 20, 2018), https://readwrite.com/2018/07/20/pop-culture-and-aihow-media-is-reshaping-public-perceptions/ (“[Depictions of AI have] inspired thousands, if not
millions of curious minds to push the boundaries of what AI can accomplish [and even take efforts
to improve our safety].”).
22
The phrase “I, for one, welcome our new computer overlords” paraphrases a quote from a 1994
episode of The Simpsons where fictional reporter Kent Brockman states “I, for one, welcome our
new insect overlords.” Mr. Jennings’ paraphrase has been used to describe our communal fear of
“robots” taking over the world. See Kevin Gannon, I, For One, Welcome Our New Robot
Overlords, GRAND VIEW UNIV.: CTR. EXCELLENCE TEACHING & LEARNING (Sept. 11,
2015), http://www.grandviewcetl.org/i-for-one-welcome-our-new-robot-overlords/; Gary Booch, I,
for One, Welcome Our New Computer Overlords, IEEE 8
(Nov. 2015), https://ieeexplore.ieee.org/stamp/stamp.jsp?arnumber=7310991.
23
Markoff, supra note 1; see also Timothy McGettigan, Star Trek for a Better Tomorrow:
Inventing the Future One Fantasy at a Time,
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3669959.
24
Tory Waldron, 3 Surprising Ways Healthcare is Using AI, DEFINITIVE HEALTHCARE (Oct. 10,
2019), https://blog.definitivehc.com/ways-healthcare-using-ai.
25
Codrin Arsene, Artificial Intelligence in Healthcare: the future is amazing, HEALTHCARE
WKLY. (Sept. 8, 2020), https://healthcareweekly.com/artificial-intelligence-in-healthcare/.
26
Id.
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and a simpler way to crowdsource and develop treatment plans.27 Its broad
inclusion in the field has created a pressing need for more, and better,
regulation.28 Improved regulation is especially critical because of the possibility
that mismanaged AI will allow for incorrect diagnosis of patients or biased
predictions and outcomes.29 In fact, numerous examples of such bias—and
attempts to manage bias—already exist,30 which raises major ethical questions
surrounding the use of AI31 and presents the issue of how to avoid health
disparities in AI.32
In this Note, I argue that AI is not being adequately managed at the federal
level. I further argue that the lack of management is largely due to a general
failure to mandate standards for data sourcing, cleaning, and testing. The health
care field is rife with examples of the effects of poor management, some of which
have immediate and devastating impacts on patients;33 however, mismanagement
27

Bernard Marr, The 9 Biggest Technology Trends That Will Transform Medicine and Healthcare
in 2020, FORBES (Nov. 1, 2019), https://www.forbes.com/sites/bernardmarr/2019/11/01/the-9biggest-technology-trends-that-will-transform-medicine-and-healthcare-in-2020/#78f74b2e72cd.
28
Kathleen Walch, AI Laws are Coming, FORBES (Feb. 20, 2020),
https://www.forbes.com/sites/cognitiveworld/2020/02/20/ai-laws-are-coming/.
29
Alvin Rajkomar et al., Ensuring Fairness in Machine Learning to Advance Health Equity,
169(12) HHS ANN. INTERN. MED. 866 (Dec. 2018) (discussing case studies and clinical
applications where machine learning harms protected groups through inaccuracy, diversion of
resources, or worsening outcomes).
30
Algorithmic bias has become a prevalent topic of debate and targeted solutions, which is evident
from the fact that there have been legislative attempts surrounding bias and that examples of AI
bias are easily located through a quick internet search. See, e.g., Terence Shin, Real-life Examples
of Discriminating Artificial Intelligence, TOWARDS DATA SCI. (June 4, 2020),
https://towardsdatascience.com/real-life-examples-of-discriminating-artificial-intelligencecae395a90070; Craig S. Smith, Dealing With Bias in Artificial Intelligence, N.Y. TIMES (Nov. 19,
2019 [updated Jan. 2, 2020]), https://www.nytimes.com/2019/11/19/technology/artificialintelligence-bias.html; Bernard Marr, Artificial Intelligence Has A Problem With Bias, Here’s
How To Tackle It, FORBES (Jan. 29, 2019),
https://www.forbes.com/sites/bernardmarr/2019/01/29/3-steps-to-tackle-the-problem-of-bias-inartificial-intelligence/?sh=674a580b7a12.
31
See Artificial Intelligence (AI) in healthcare and research, NUFFIELD COUNCIL ON BIOETHICS
(May 2018), https://www.nuffieldbioethics.org/assets/pdfs/Artificial-Intelligence-AI-inhealthcare-and-research.pdf (providing examples of some of the many ethical questions raised by
use of AI in health care).
32
See, e.g., W. Nicholson Price II, Risks and remedies for artificial intelligence in health care,
BROOKINGS (Nov. 14, 2019), https://www.brookings.edu/research/risks-and-remedies-forartificial-intelligence-in-health-care/; Sara Gerke et al., Ethical and legal challenges of artificial
intelligence-driven health care, in ARTIFICIAL INTELLIGENCE IN HEALTHCARE 295 (2020) (“It is []
vital that AI makers are aware of [the] risk and minimize potential biases at every stage in the
process of product development.”).
33
See infra Part II(B).

112

Managing the Medical Matrix:A “DAIS” for Artificial Intelligence in Health Care (and
Beyond)

of AI is not limited to health care alone. The potential problems that arise from
lack of oversight span across industry lines. Thus, no single industry or existing
federal agency can claim full ownership of, or expertise in, AI as a tool. I
therefore propose that the best possible solution would be to form an entirely new
top-level federal agency. This new agency would be tasked with creating federally
mandated standards for ethical AI data sourcing, cleaning, and testing across
industries. It would provide comprehensive management of AI datasets that do
not fall under the umbrella of an existing agency such as the Food & Drug
Administration (FDA). I further propose that the new regulatory body be named
the “Department of Artificial Intelligence Standardization,” or DAIS.
DAIS would be responsible for devising and distributing a baseline set of
rules across agencies. It would provide consistency of standards, much like the
“guideline” AI standards proposed by the National Institute of Standards and
Technologies (NIST),34 but will bear the weight of federal regulatory authority
rather than policy guidelines. DAIS would alleviate some of the mounting
pressure within other agencies35 to create new rules for AI. DAIS would also
provide space for tailored oversight of industry-specific AI by employing
specialists who are tasked with collaboration between DAIS and other agencies
like the FDA.
Part II of this Note will provide a background on what AI and machine
learning (“ML”) are and how they are used in health care. Part III will speak to
the issues that are most important in creation of fair and unbiased AI. Part IV will
discuss existing attempts to regulate use of AI both in health care and more
broadly. Finally, Part V will delve into the proposed DAIS solution and explain
possibilities for rulemaking.

34

NIST has outlined a draft plan for developing technical standards for AI and appropriate federal
involvement. See NATIONAL INST. STANDARDS & TECH., U.S. LEADERSHIP IN AI: A PLAN FOR
FEDERAL ENGAGEMENT IN DEVELOPING TECHNICAL STANDARDS AND RELATED TOOLS (submitted
Aug. 2019),
https://www.nist.gov/system/files/documents/2019/08/10/ai_standards_fedengagement_plan_9aug
2019.pdf [hereinafter NIST AI STANDARDS].
35
See, e.g., DAVID FREEMAN ENGSTROM ET AL., GOVERNMENT BY ALGORITHM: ARTIFICIAL
INTELLIGENCE IN FED. ADMIN. AGENCIES, REP. TO THE ADMIN. CONFERENCE OF THE U.S. (2020).
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II.

Algorithms and AI: Magic Words in Health Technology
a.

Defining Algorithms and AI

Algorithms are mathematical models intended to solve a finite set of
problems.36 They are procedures that can generate, or become a part of a
“predictive model,” which is the program itself.37 In other words, algorithms use
training data to create a model—the “thing” we use to process new data.38 When a
user or system inputs a new set of data to a predictive model, the model produces
output based on how it was trained by the initial algorithm; it uses data
mining/input and probability to forecast specific outcomes.39 AI is something
more than a predictive model. AI uses models to perform frequent, high-volume,
computerized tasks,40 and it comes in several forms.41 ML is one form of AI,
where a machine using an algorithm “can improve at its programmed, routine,
automated tasks”42—in other words, ML becomes smarter as it processes more
data. ML generally refers to a model based on algorithms that are intended to
optimize and automate learning processes.43 It is what we typically think of when
we talk about AI as being “smart.” When we envision future androids, like “Data”
of Star Trek: The Next Generation44 or “David” from the film A.I. Artificial
36

Sebastian Sigloch, What are Algorithms and does it matter?, TOWARDS DATA SCI. (Dec. 17,
2019), https://towardsdatascience.com/what-are-algorithms-really-and-does-it-matter75d129d61ed0.
37
Jason Brownlee, Difference Between Algorithm and Model in Machine Learning, MACHINE
LEARNING MASTERY (Apr. 29, 2020), https://machinelearningmastery.com/difference-betweenalgorithm-and-model-in-machine-learning/ [https://perma.cc/2RMP-D8VF].
38
Id.
39
Stacia Damron, AI Academy: What’s the difference between forecasting and predictive
modeling?, ONEMODEL.CO, https://www.onemodel.co/blog/ai-academy-forecasting-vs-predictivemodeling (last visited Mar. 13, 2021) [https://perma.cc/YAT9-WVN7].
40
Artificial Intelligence: What it is and why it matters, SAS,
https://www.sas.com/en_us/insights/analytics/what-is-artificial-intelligence.html (last visited Apr.
19, 2022).
41
Yulia Gavrilova, Artificial Intelligence vs. Machine Learning vs. Deep Learning: Essentials,
SEROKELL (Apr. 8, 2020), https://serokell.io/blog/ai-ml-dl-difference.
42
Id.
43
See generally Ravindra Parmar, Demystifying Optimizations for machine learning, TOWARDS
DATA SCI. (Sept. 5, 2018), https://towardsdatascience.com/demystifying-optimizations-formachine-learning-c6c6405d3eea.
44
The android “Data,” played by Brent Spiner, was renowned as an “ethical” artificial life form in
the Star Trek: The Next Generation series. Data struggled regularly with his desire to become
more human. The show considered issues of consciousness and intentionality, and suggested that
the ability to adapt—thus, the core of machine learning—was central to Data’s development in
becoming closer to humanity. See Victor Grech, Mariella Scerri, & David Zammit, Evil Doctor,
Ethical Android: Star Trek’s Instantiation of Consciousness in Subroutines, 1 J. SCI. FICTION 9, 11
(2017).
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Intelligence,45 who learn as they gain real-world experience, we are imagining
future advanced applications of ML.
For purposes of this Note, the terms “algorithm,” “AI,” and “ML” will
normally be collaboratively referred to as “AI,” though in some instances, this
Note will specifically refer to ML for the sake of clarity. Another important
distinction is the difference between “locked AI” and “dynamic AI” as defined by
the FDA. A locked algorithm provides the same result each time the same input is
applied, whereas dynamic or adaptive algorithms change over time while
continuously learning.46 Presently the FDA only regulates locked AI, although
dynamic AI does exist in health care.47 It does so via the authority to regulate
devices granted by the federal Food, Drug, and Cosmetic Act.48 The FDA has
acknowledged that this limitation is problematic, but has also stated that it does
not wish to impede development of learning algorithms.49
b.

Current Use of and Future Potential for AI in Health
Care

Abundant examples of the growing use of AI in health care can be found
anywhere you turn, as AI is already proving valuable in a wide variety of
applications. Applications range from low-level decisions like staffing
considerations based on hourly availability50 to highly impactful areas such as

45

“David,” a humanoid “mecha” in Spielberg’s A.I., exhibits an evolving emotional connection to
the human who unboxes him; throughout the film, he undergoes an existential crisis over whether
he can become a real boy. The film is fraught with examples of living, learning androids, and
David is the first of his kind that can experience true emotional connection. See Idioa Sanazar,
Robots and Artificial Intelligence: New challenges of journalism, 27 DOXA COMMUNICACIÓN 295,
297 (2018).
46
U.S. FOOD & DRUG ADMIN., EXEC. SUMMARY FOR THE PATIENT ENGAGEMENT ADVISORY
COMM. MTG.: ARTIFICIAL INTELLIGENCE (AI) AND MACHINE LEARNING (ML) IN MEDICAL
DEVICES (Oct. 22, 2020) [hereinafter FDA EXECUTIVE SUMMARY]; Stan Benjamens et al., The
state of artificial intelligence-based FDA-approved medical devices and algorithms: an online
database, 3 NPJ DIGITAL MEDICINE 118 (2020).
47
Benjamens, supra note 46.
48
Food, Drug, & Cosmetic Act, 21 U.S.C. ch. 9 § 301 et seq.
49
See infra Part III(A)(1).
50
AI-Assisted Decision Making: Health care’s Next Frontier, HEALTH CATALYST (Jan. 30, 2020),
https://www.healthcatalyst.com/insights/ai-assisted-decision-making-health cares-next-frontier.
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drug development,51 clinical research,52 and diagnosing and treating patients.53
Oncology is one of the most promising areas for the use of predictive models. AI
can assist in detecting breast cancer,54 predicting lung cancer,55 and classifying
types of cancer.56 Several oncological research institutions have begun
investigating use of AI in precision medicine, which attempts to analyze large
genomic and molecular datasets.57 Furthermore, there is a call for increased use of
AI in cancer immunotherapy.58
In hospital and primary care settings, AI is optimizing physicians’ “care
pathways,”59 which are processes designed to aid in decision-making for specific
groups of patients.60 AI has also been utilized to help predict the care needs of
trauma patients based on those patients’ symptoms and histories.61 Algorithms are
51

See generally U.S. GOV’T ACCOUNTABILITY OFF., ARTIFICIAL INTELLIGENCE IN HEALTH CARE:
BENEFITS AND CHALLENGES OF MACHINE LEARNING IN DRUG DEVELOPMENT (Dec. 2019)
[hereinafter GAO AI REPORT].
52
Id.; Anmol Arora, Conceptualising Artificial Intelligence as a Digital Health care Innovation:
An Introductory Review, 13 MED. DEVICES (AUCKLAND) 223 (2020),
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7455610/.
53
See Alexis S. Gilroy et al., Artificial Intelligence and Health Care—Key Regulatory
Considerations for U.S. Operations, JONES DAY (Jan. 2018),
https://www.jonesday.com/en/insights/2018/01/artificial-intelligence-and-health-carekey-regulat.
54
Alejando Rodriguez-Ruiz et al., Stand-Alone Artificial Intelligence for Breast Cancer Detection
in Mammography: Comparison With 101 Radiologists, 9 J. NAT. CANCER INST. 111 (2019).
55
Diego Ardila et al., End-to-end lung cancer screening with three-dimensional deep learning on
low-dose chest computed tomography, 25 NATURE MEDICINE 954 (2019).
56
See generally Vadim Zhernovoy, Applying Deep Learning to Classify Skin Cancer Types,
APRIORIT, https://www.apriorit.com/dev-blog/647-ai-applying-deep-learning-to-classify-skincancer-types (last visited Apr. 19, 2022) (discussing specific steps that can be taken to screen for
and classify skin cancers using deep learning).
57
Institutions such as DeepThink Health, the American Association for Cancer Research, and the
American Society of Clinical Oncology are using precision medicine to investigate treatment
options for cancer. See mkatip, Big Data and Clinical Genomics, DEEPTHINK HEALTH NEWS,
https://www.deepthinkhealth.com/2019/03/27/big-data-and-clinical-genomics/
(last visited Apr. 19, 2020).
58
Mike Scott, Powerful push to use AI for cancer immunotherapy, CASE W. RES. UNIV.: THE
DAILY, https://thedaily.case.edu/powerful-push-for-ai-for-cancer-immunotherapy/ (last visited
Apr. 19, 2020).
59
Michael Sanders, How using artificial intelligence enabled Flagler Hospital to reduce clinical
variation, HEALTHCARE FINANCIAL MGMT. ASSN. (Jan. 17, 2020),
https://www.hfma.org/topics/financial-sustainability/article/using-artificial-intelligence-enabledflagler-hospital-reduce-clinical-variation.html.
60
Guus Schrjivers et al., The care pathway: concepts and theories: an introduction, 12 (Special
Ed.) INT’L J. INTEGRATED CARE e192 (2012).
61
Nehmiah T. Liu et al., Development and Validation of a Machine Learning Algorithm and
Hybrid System to Predict the Need for Life-Saving Interventions in Trauma Patients, 52 MED. &
BIOLOGICAL ENGINEERING & COMPUTING 193 (2014).
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prevalent in other areas of health care including cardiology,62 where use of data
sensors, remote monitoring, and connected data from multiple wearable sources
aids in the study of heart failure.63 AI is also increasingly present in wellness
products.64 For example, “smart” home-based sensors can monitor homebound
patients and, when coupled with predictive algorithms, can forecast those
patients’ care needs.65 The increased prevalence of wellness technologies that can
manage and predict health care needs based on personal health data66 should be of
concern to regulators, as the FDA only oversees medical devices at this time.67
AI will inevitably continue to be of paramount importance in health
technologies. As recently as 2020, several of the “latest” tools in health
technology included virtual assistants, early identification of melanoma, “robotic
assisted therapy,” and software to aid in the capture of echocardiographic images
for diagnosis.68 With the rapid pace of software development,69 the possibilities
are seemingly endless. The health care industry and society in general are facing a
“paradigm shift in the level of AI technology and its adoption.”70 This is a
62

See Arora, supra note 52 (discussing use of AI in cardiology and radiology).
Patrik Bachtiger et al., Artificial Intelligence, Data Sensors, and Interconnectivity: Future
Opportunities for Heart Failure, 6 CARDIAC FAILURE REV. 11 (2020),
https://www.ncbi.nih.gov/pmc/articles/PMC7265101.
64
See generally Lydia Kostopoulos, The Emerging Artificial Intelligence Wellness Landscape:
Opportunities and Areas of Ethical Debate, TRANSFORMATIVE TECH (Feb. 25, 2019),
https://www.transformativetech.org/blog-single?id=3103 (providing examples of types of AI in
wellness products including Fitbit, Apple Watch, virtual therapists, smart journaling, and smart
sleep devices).
65
For an example of a proposed use of IoT in home monitoring and care predictions, see Olutosin
Taiwo & Absalom E. Ezugwu, Smart health care support for remote patient monitoring during
COVID-19 quarantine, 20 INFORMATICS MED. UNLOCKED (2020). One company attempting to
leverage this technology is VINYA Intelligence, a startup offering patient monitoring via a sensor
system that detects daily activities and offers “identification of early warning signs.” See What is
the VINYA app?, VINYA, https://www.vinya.com/vinya-app (last visited Apr. 19, 2022).
66
AI-Assisted Decision Making: Healthcare’s Next Frontier, HEALTH CATALYST (Jan. 30, 2020),
https://www.healthcatalyst.com/insights/ai-assisted-decision-making-healthcares-next-frontier.
67
See generally FDA EXECUTIVE SUMMARY, supra note 46.
68
Micah Castelo, The Future of Artificial Intelligence in Healthcare, HEALTHTECH (Feb. 26,
2020), https://healthtechmagazine.net/article/2020/02/future-artificial-intelligence-healthcare.
Castelo implies that this is just the beginning of an “explosion in innovation.”
69
Adam Bohr & Kaveh Memarzadeh, The rise of artificial intelligence in healthcare applications,
1 A.I. HEALTHCARE 25, 26 (2020) (“Although research in AI for various applications has been
ongoing for several decades, the current wave of AI hype is different from the previous ones. A
perfect combination of increased computer processing speed, larger data collection data libraries,
and a large AI talent pool has enabled rapid development of AI tools and technology, also within
healthcare.”).
70
Id. (“[Rapid development of AI] is set to make a paradigm shift in the level of AI technology
and its adoption and impact on society.”).
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thrilling and dangerous path: medical algorithms may require “special policies
and guidelines” for oversight due to concerns about their safety and efficacy.71
III.

The Wild West: Untamed Data and Unregulated Practice

The present state of AI and digital health research in health care has been
likened to the “wild west,”72 in terms of both the data itself73 and the practice of
using AI in health care. The lack of sufficient regulation tailored for AI is also of
concern.74 At the development end, which is arguably the most important aspect
to consider in future regulation, AI developers face persistent issues in data
collection (i.e., poor quality data or lack of uniformity of training data).75
“Training data” is the initial set of data that acts as a baseline or foundation for
teaching a model how to evaluate live datasets.76 These quality issues are
71

Sandeep Reddy et al., A governance model for the application of AI in health care, 27 J. AM.
MED. INFORMATICS ASS’N 491, 492 (2019),
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7647243/pdf/ocz192.pdf (“Algorithms that are
unexplainable in their decision making, change continuously with use, and autoupdate, perhaps
with features that go beyond the initial approved clinical trials, may require special policies and
guidelines. Concerns also emerge about the safety and efficacy of AI medical software that does
not necessarily align with current models of care delivery. Regulatory standards to assess AI
algorithmic safety and impact are yet to be formalized in many countries. This can both present
barriers to entry of AI in health care and enable unsafe practices in which AI is already being used
in health care.”).
72
See, e.g., Camille Nebeker et al., Building the case for actionable ethics in digital health
research supported by artificial intelligence, 17 BMC MEDICINE 137 (2019) (“As the ‘Wild West’
of digital health research unfolds, it is important to recognize who is involved, and identify how
each party can and should take responsibility to advance the ethical practices of this work.”);
WILLIAMS & NICKL, ARTIFICIAL INTELLIGENCE & MEDICINE IN ILLINOIS (July 13, 2020),
https://www.williamsnickl.com/illinois-license-defense-law-idfpr/artificial-intelligence-medicinein-illinois (“Over the next few years, decisions on how and when to use the new advancements [in
AI] may look like the Wild West.”).
73
See Gilroy et al., supra note 53 (“As the use of AI in the clinical space increases and evolves,
legal and regulatory risk can escalate, particularly with the growing attention and unique
application of traditional regulatory principles not yet attuned to AI.”).
74
See NAT’L ACAD. MED., ARTIFICIAL INTELLIGENCE IN HEALTH CARE: THE HOPE, THE HYPE, THE
PROMISE, THE PERIL (Michael Matheny et al., eds. 2019) (“AI tools are being implemented in an
environment of inadequate regulation and legislation.”).
75
Hayden Field, A Lack of Diverse Data Is Hurting Healthcare AI. Here’s How, MORNING BREW:
EMERGING TECH (Nov. 9, 2020), https://www.morningbrew.com/emergingtech/stories/2020/11/09/lack-diverse-data-hurting-healthcare-ai-heres (“An ML model is only as
good as the data it’s trained on. And issues with that data—like narrow scope and existing
biases—can easily compound over time. For example: A model trained mostly on medical data
from a predominantly white area could have trouble diagnosing black women. Accounting for
these types of discrepancies is key, especially before an AI healthcare product goes to market.”).
76
What is Training Data?, APPEN (Apr. 14, 2020), https://appen.com/blog/training-data/;
Alexandre Gonfalonieri, How to Build a Data Set For Your Machine Learning Project, TOWARDS
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primarily due to inconsistencies in data collection, data definitions, and the
absence of widespread shared standards for training data.77 The lack of shared
standards in turn leads to inaccurate output and unintended disparities, as nondiverse datasets will lead to biased output.78 Because the quality issue stems
directly from the data input, sourcing, and testing phases, any solution must speak
to standardization.
a.

Taming the Beast: Clean Data, Interoperability, and
Data Standardization

The greatest need in creating a functioning AI is well-curated data,79 yet
health data is rife with errors.80 Without mandated standards for clean data, data
sourcing and collection are major stumbling blocks in the development of
accurate predictive models.81 Although there are examples of data standardization
in health,82 existing standardization practices are nothing more than unenforceable
guidelines. The health industry is faced with three questions: 1) how to address
the data entry issues prevalent in EHR systems; 2) how to ensure clean data; and
3) how to enforceably standardize its data, which may be a task best suited to AI
developers.
DATA SCI. (Feb. 13, 2019), https://towardsdatascience.com/how-to-build-a-data-set-for-yourmachine-learning-project-5b3b871881ac.
77
See, e.g., Pam Arlotto, Artificial intelligence: 5 realities for financial leaders, HEALTHCARE FIN.
MGMT. ASSN. (Feb. 4, 2020), https://www.hfma.org/topics/hfm/2020/february/artificialintelligence--5-realities-for-financial-leaders.html (“Problems in data collection accuracy, variable
data definitions and limited interoperability across disparate systems create data quality issues.”).
78
Bibb Allen et al., The Role of an Artificial Intelligence Ecosystem, ARTIFICIAL INTELLIGENCE IN
MEDICAL IMAGING RADIOLOGY 300 (Erik Ranschaert et al., eds., 2019) (“Both developers and
consumers of AI applications in health care . . . must be cognizant of the broad diversity in patient
populations so that there will be similar diversity in training data so that algorithms will be free of
unintended bias.”).
79
See Divya Singh (@divyasingh456), The Role of Data Curation in Big Data, DATA SCI. CENT.:
BLOG (Apr. 28, 2019, 4:00 PM), https://www.datasciencecentral.com/the-role-of-data-curation-inbig-data/.
80
A 2019 study found that 21.1% of survey participants found errors in their health reports, and
42.3% of those described “serious” or very serious mistakes. Sigall K. Bell et al., Frequency and
Types of Patient-Reported Errors in Electronic Health Record Ambulatory Care Notes, 3 JAMA
NETWORK OPEN 1, 4 (2020).
81
See Jessica Kent, Data Quality, Equity Essential for Artificial Intelligence Use, HEALTH IT
ANALYTICS (Dec. 19, 2019), https://healthitanalytics.com/news/data-quality-equity-essential-forartificial-intelligence-use (“Methods to assess data quality are often not standardized or
nonexistent.”).
82
See, e.g., Introduction to HL7 Standards,
HL7 INT’L, https://www.hl7.org/implement/standards/index.cfm (last visited Jan. 30, 2021)
(listing health care standards frameworks for electronic health information).
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1.

Electronic Records Data: “Garbage In/Garbage
Out”

EHRs, which focus on a “total health” picture of a patient, and electronic
medical records (“EMR”), which are the digital equivalent of paper patient
charts,83 are substantial sources of datasets for health care AI. Developers who
create applications for hospital systems or medical research facilities frequently
obtain datasets from EHRs and EMRs.84 EHRs contain rich data85 including
clinical history, laboratory tests, treatments, and prognoses,86 and databases
sourced from their contents are extremely valuable potential sources for clinical
research.87 Yet because of a lack of standardization, records sourced from one
institution or research facility may have completely different characteristics than
those from another.88 Some hospital systems even employ multiple types of EHRs
and EMRs internally that do not speak to each other—for example, an EMR from
a hospital’s emergency department may have no connection to another from its
primary care offices.89 In 2018, Healthcare IT News reported that the average
83

An electronic medical record (EMR) is a digital version of a paper patient chart, while an EHR
focuses on the “total health” of the patient and are designed to “reach out beyond” the organization
that compiles the record. Peter Garrett & Joshua Seidman, EMR vs EHR: What is the Difference?,
HEALTHIT (Jan. 4, 2011), https://www.healthit.gov/buzz-blog/electronic-health-and-medicalrecords/emr-vs-ehr-difference.
84
Ayaka Shinozaki, Electronic Medical Records and Machine Learning in Approaches to Drug
Development, ARTIFICIAL INTELLIGENCE IN ONCOLOGY DRUG DISCOVERY AND DEVELOPMENT
(John W. Cassidy & Belle Taylor, eds.) (2020).
85
Effy Vayena & Lawren Madoff, Navigating the Ethics of Big Data in Public Health, in THE
OXFORD HANDBOOK OF PUBLIC HEALTH ETHICS 354, 355 (Anna C. Mastroianni et al. eds., 2019).
86
Young Juhn & Hongfang Liu, Artificial intelligence approaches using natural language
processing to advance EHR-based clinical research, 145 J. ALLERGY & CLINICAL IMMUNOLOGY
463 (2020).
87
Id.
88
See Grant Barrick, 4 Reasons Why EHR Interoperability is a Mess (and How to Fix It), DATICA
BLOG (June 17, 2019), https://datica.com/blog/reasons-ehr-interoperability-is-a-mess-and-how-tofix-it (“Hospital consolidation is accelerating, which means that the resulting multi-hospital health
systems and health networks are using EHR systems from different vendors. These EHR vendors
are often creating proprietary communication and language protocols that make them unable to
communicate with other EHRs. Providers of all types and sizes throughout the health care
continuum must then find ways to integrate the different EHRs both inside and outside of their
own facilities.”).
89
See Jeff Lagasse, How disparate EHR systems, lack of interoperability contribute to physician
stress, burnout, HEALTHCARE FIN. (June 29, 2018),
https://www.healthcarefinancenews.com/news/how-disparate-ehr-systems-lack-interoperabilitycontribute-physician-stress-burnout (“What a physician might have in their physician care practice
might be Athena, or an EMR customized to their workflow, or a public-type vendor. When they
go in to do rounding, it's usually an Epic or a Cerner, a large system. They have to deal with three
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hospital had 16 disparate EMR vendors in use at its affiliated practices.90 Even
those systems that create records with similar characteristics may provide
incomplete data due to inconsistencies in input.91 These discrepancies lead
directly to issues in creation of training datasets and algorithmic testing;92
sourcing patient data from different systems or in different formats “makes ML
more difficult and complex” and can create poor output.93 The lack of
interoperability of existing data systems results in the use of necessarily
incomplete datasets in testing.94 This can tangibly impact patients: a gap in critical
information may lead to adverse events at the direct care level,95 and that same
gap may cause incorrect algorithmic predictions for care needs.96
or more EMR systems depending on how they're caring for their patients. If there is no
standardization . . . then imagine the challenge of only having a few minutes for the patients and
having to provide a full realm of care for them.”).
90
Tom Sullivan, Why EHR data interoperability is such a mess in 3 charts, HEALTHCARE IT
NEWS (May 16, 2018), https://www.healthcareitnews.com/news/why-ehr-data-interoperabilitysuch-mess-3-charts.
91
See Cassandra Willyard, Can AI Fix Electronic Medical Records?, SCI. AM. (Feb. 1, 2020),
https://www.scientificamerican.com/article/can-ai-fix-electronic-medical-records (“EHRs include
a wide variety of unstructured data . . . For example, a strawberry allergy might end up
documented in the clinical notes rather than being listed in the allergies box. In such cases, a
model that looks for allergies only in the allergy section of the EHR ‘is built off of inaccurate
data.’”).
92
For a discussion of some of the types of issues that can be raised by missing or inconsistent
EHR data, see Nariman Noorbakhsh-Sabet et al., Artificial Intelligence Transforms the Future of
Health Care, 132 AM. J. MED. 795, 799 (2019).
93
Any datasets that are sourced from multiple systems using different EHRs will themselves be
divergent, since independent EHR systems employ proprietary coding and data standards. See Dan
Soule, The Biggest Barriers to
Healthcare Interoperability, HEALTH CATALYST (Apr. 22, 2020), https://www.healthcatalyst.com/
insights/healthcare-interoperability-barriers-solutions.
94
The Future of Clinical Interoperability in Healthcare, FORESEE MED. (Aug. 24, 2020),
https://www.foreseemed.com/blog/clinical-interoperability-in-healthcare (“As you would expect,
the lack of interoperability in healthcare also hinders development, which may be the biggest
missed opportunity for the health interoperability ecosystem. Innovators in healthcare face
challenges accessing data, integrating into highly-customized environments, and scaling semantic
interoperability across a variety of data landscapes.”).
95
See Jason Walonoski et al., Validation and Testing of Fast Healthcare Interoperability
Resources Standards Compliance: Data Analysis, 6(4) J. MED. INFORMATICS (2018) (“The lack of
interoperability leads to gaps in critical information at the point of care . . . An inpatient study
found that 18% of medical errors leading to adverse drug events could be traced back to missing
data in the patient's medical record.”).
96
See Moritz Lehne et al., Why digital medicine depends on interoperability, 2 NPJ DIGITAL MED.
79 (2019). Lehne et al. discuss the need for interoperability and multiple data sources for precision
medicine in particular, but note that data processing is difficult due to the current infrastructure.
(“Unfortunately, today’s digital health infrastructure makes large-scale data processing across IT
systems still unnecessarily difficult . . . [R]unning algorithms on unstructured, non-standardized
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Because EHRs contain text entry fields, abundant sources of patient
information and potential training data can be gained via NLP.97 NLP provides
incredible and valuable opportunities to glean far more information from EHRs
than that which can be obtained by pulling pre-sorted data from labeled fields.98
However, NLP is not always available or accurate, so precious data can be left
unused in text fields.99 Those text fields may also be the sole sources of
socioeconomic, behavioral, or other non-medical information obtained about a
patient during their visit.100 That untapped data can be crucial in creating a full,
connected picture of a patient’s health,101 and may be invaluable in creating a
predictive model.102
A common problem in text entry is “garbage in/garbage out” (“GI/GO”)
where poorly created, poorly curated datasets create poor output.103 Consistency
data can introduce errors that distort analysis results. An AI algorithm programmed to identify, for
example, diabetes patients from unstructured text could erroneously select patients with a family
history of diabetes, not actual diabetes (not to mention the different types and subgroups of
diabetes that could easily be confused) . . . This can introduce systematic biases, which
compromise the validity of analysis results and which will eventually undermine trust in digital
health technologies . . . [M]odern AI algorithms could do more harm than good—not because their
calculations are wrong but because they rely on questionable input.”).
97
See “Healthcare NLP: The Secret to Unstructured Data’s Full Potential,” HEALTH CATALYST
(Apr. 2, 2019), https://www.healthcatalyst.com/insights/how-healthcare-nlp-taps-unstructureddatas-potential.
98
Id.
99
See VERA EHRENSTEIN ET AL., TOOLS AND TECHNOLOGIES FOR REGISTRY INTEROPERABILITY,
REGISTRIES FOR EVALUATION PATIENT OUTCOMES: A USER’S GUIDE (3rd Edition, Addendum 2
[Internet]) (R. Gilcrich et al. eds., 2019) (“[E]xisting text mining tools and natural language
processing applications have limited accuracy in extracting information from free text . .
. [This] increases the likelihood of low data quality (e.g., missing data) when data are extracted
from structured EHR data only.”).
100
See Elham Hatef et al., Assessing the Availability of Data on Social and Behavioral
Developments in Structured and Unstructured Electronic Health Records, 7 JMIR MED.
INFORMATICS (2019) (“Health care systems seeking access to SBDH [social and behavioral
determinants of health] data through their electronic health records (EHRs) face various challenges
in searching and summarizing structured and unstructured data (clinical free-text notes).”).
101
Id.
102
One recent study discusses the use of free-text processing to improve accuracy of predictions,
indicating that examination of “socioeconomic, demographic and clinical factors” during
emergency visits and inclusion of unstructured textual data “provided significant improvement in
accuracy.” Xingyu Zhang et al., Use of natural language processing to improve predictive models
for imaging utilization in children presenting to the emergency department, 19 BMC MED.
INFORMATICS & DECISION MAKING 287 (2019).
103
Monique F. Kilkenny & Kerin M. Robinson, Data Quality: “Garbage in—Garbage out”,
47 HEALTH INFO. MGMT. J. 103, 103 (2018).
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of input—that is, using standard input methods and standard language—should be
considered by everyone involved at the data entry level, otherwise data analytics,
applications or business processes will be unreliable.104 Established procedures
are needed to ensure that good quality data are collected in the health information
management and care systems in order to avoid the GI/GO pitfall.105 However,
many doctors have claimed to experience EHR-related stress or burnout because
of the need to use EHRs to record patient encounters,106 which leads to inaccurate
text entry and information errors.107 This presents a genuine need for
standardization of NLP and input methods and, perhaps, use of automated
systems to ease input fatigue.108 One potential method of easing fatigue is
automated voice recognition and voice typing, which is use of NLP at the input
rather than retrieval stage.109
2.

Taking Out the Trash: Clean Predictions

Tied to the GI/GO concern is a lack of mandated “clean data”
requirements.110 “Clean data” is attained by correcting and deleting inaccurate
records from a dataset,111 and this process is of utmost importance when creating
predictive models.112 Data entry errors and duplicate records113 abound in EHR
datasets. At least half of EHRs may contain an error which is “nontrivial,”114 and
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Id.
Id.
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Christopher Curley, Doctors Tell Us Why Electronic Health Records Are Causing Burnout,
HEALTHLINE (Feb. 6, 2019), https://www.healthline.com/health-news/why-electronic-healthrecords-are-burning-out-doctors#1.
107
Id.
108
Thomas H. Davenport et al., Using AI to Improve Electronic Health Records, HARV. BUS. REV.
(Dec. 13, 2018), https://hbr.org/2018/12/using-ai-to-improve-electronic-health-records.
109
Id.
110
Bill Siwicki, Clean data, AI advances and provider/payer collaboration will be key in 2020,
HEALTHCARE IT NEWS (Jan. 27, 2020), https://www.healthcareitnews.com/news/clean-data-aiadvances-and-providerpayer-collaboration-will-be-key-2020 (“There is no machine learning
without clean data—meaning the data needs to be aggregated, normalized and deduplicated.”).
111
See Cem Dilmegani, Data Cleaning in 2021:What it is, Steps to Clean Data & Tools, AI
MULTIPLE: RESEARCH (Jan. 6, 2021), https://research.aimultiple.com/data-cleaning/.
112
Id.
113
See Jackie Drees, Survey: Providers identify data entry errors as biggest contributor to
duplicate medical records, BECKER’S HEALTH IT (Feb. 12, 2020),
https://www.beckershospitalreview.com/ehrs/survey-providers-identify-data-entry-errors-asbiggest-contributor-to-duplicate-medical-records.html.
114
Data entry errors are a common source of inaccuracies: at least half of EHRs may contain an
error related to medication lists, erroneous examination findings, or a lack of critical information.
Bell et al., supra note 80, at 2.
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poor data quality “inevitably leads” to poor algorithmic performance.115 The
absence of clean data is creating challenges in health analytics116 as well as
predictive modeling. Since doctors and health care professionals are already
overburdened with data input fatigue, the solution must be to require data
cleaning by internal technical departments and further require secondary
verification of cleaning by the companies intending to use the data in their
development processes. Cleaning tasks should include exporting raw data,
checking for completion and accuracy, clearing duplicates, and verifying
consistency of field information.117
3.

Standardization: Knowing What to Expect When
You’re Extracting

A sister issue to clean data is standardization of dataset curation and
collection practices. Collection of training data is itself “like the wild west,”118 as
many software companies do not have systems in place to ensure “collection and
curation of balanced or representative datasets.”119 This renders them unable to
hazard a guess as to whether their work will lead to biased results, which is
problematic: bias is one of the core issues facing AI developers,120 and bias is
visibly impactful in the health context.121 Standardization could help to eliminate
some or even a majority of implicit bias at the development stage.

115

Sharona Hoffman & Andy Podgurski, Artificial Intelligence and Discrimination in Health
Care, 19 YALE J. HEALTH POL’Y, L., & ETHICS 1, 13 (2020).
116
See Chris Nerney, Poor data can sabotage AI initiatives in healthcare, DXC TECHNOLOGY:
BLOG (Mar. 3, 2020), https://blogs.dxc.technology/2020/03/03/poor-data-can-sabotage-aiinitiatives-in-healthcare/ (discussing a 2019 survey of health care providers which indicated that
66% of respondents cited data entry errors in EHRs and 38% said a “lack of data governance” was
a barrier to their research).
117
For a general discussion of data cleaning principles and tasks, see Dlmegani, supra note 111.
118
Kenneth Holstein et al., Improving Fairness in Machine Learning Systems: What Do Industry
Practitioners Need? CHI ’19: PROCEEDINGS OF THE 2019 CHI CONFERENCE ON HUMAN FACTORS
IN COMPUTING SYSTEMS 1 (May 2019), https://dl.acm.org/doi/pdf/10.1145/3290605.3300830.
119
Id.
120
See, e.g., Richmond Alake, Algorithm Bias In Artificial Intelligence Needs To Be Discussed
(And Addressed), TOWARDS DATA SCI. (Apr. 27, 2020),
https://towardsdatascience.com/algorithm-bias-in-artificial-intelligence-needs-to-be-discussedand-addressed-8d369d675a70; James Manyika et al., What Do We Do About the Biases in AI?,
HARV. BUS. REV. (Oct. 25, 2019), https://hbr.org/2019/10/what-do-we-do-about-the-biases-in-ai.
121
Professors Hoffman and Podgurski recently authored a paper that speaks directly to the bias
issue in health-related AI, in which they discuss discriminatory effects of AI in health and
disadvantages experienced by specific groups of patients as a result of the use of AI. Hoffman &
Podgurski, supra note 115, at 12–15.
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While some standards do exist for health data, they are not well-developed
and not consistent. The health industry is striving to implement and develop sets
of standards across practice areas, but recent articles and studies have indicated
that those standards are not consistently adopted or used effectively.122 Rather
than attempting to adhere to generalized policy, health organizations would be
better served by federal requirements ensuring that data specifications are
prioritized and “well documented through a repeatable process.”123
The lack of standardization of data curation methods can lead directly to
bias in algorithmic output.124 In other words, “wild west” data at the input and
testing phases of AI development can lead directly, and inadvertently, to an
algorithm’s unfairly biasing against members of the groups it was designed to
serve. As recently as October 2020, the FDA’s “Patient Engagement Advisory
Committee” spoke of the need to focus upon datasets in the effort to prevent
bias.125 The chief medical officer stated: “In many instances, AI and ML devices
may be learning a worldview that is narrow in focus, particularly in the available
training data, if the available training data do not represent a diverse set of
patients.”126 A lack of diverse, clean input data can cause algorithms to
misdiagnose patients who did not fit the mold created by that input data.127 The
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123
OFC. NAT’L COORD. HEALTH INFO. TECH., PATIENT DEMOGRAPHIC DATA QUALITY
FRAMEWORK: INTRODUCTION, https://www.healthit.gov/playbook/pddqframework/introduction/ (last visited Apr. 19, 2022).
124
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2020), https://www.healthcareitnews.com/news/fda-highlights-need-address-bias-ai.
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Id.
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See, e.g., Dave Gershgorn, If AI Is Going to be the World’s Doctor, It Needs Better
Textbooks, QUARTZ (Sept. 6, 2018), https://qz.com/1367177/if-ai-is-going-to-be-the-worldsdoctor-it-needs-better-textbooks (discussing an instance where AI had been trained on the voices
of English speakers of a “particular Canadian dialect” and misconstrued non-native speakers’
speech as indicative of Alzheimer’s disease).
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standardization task is one that should be managed and regulated at the
development level.
b.

The Significant Issue of Disparity

The health care industry is rife with bias, both algorithmic and in standard
practice.128 For algorithms, preventing bias requires oversight aimed at the initial
data sourcing and testing phases. The increasingly prevalent use of algorithms
without such oversight leads to situations where specific demographic groups are
excluded from beneficial treatments and therapies,129 which may be a violation of
those groups’ civil rights.130 It can also lead to altogether incorrect predictions
about the types of treatments that may be effective for specific patients.131
Biased output from a health-focused algorithm is a serious, possibly lifethreatening issue.132 That issue becomes even more important during a
pandemic.133 The introduction of automated decision-making systems to aid in
health care is potentially disastrous for low-income patients, minorities, and
women, as AI may “create self-fulfilling prophesies that confirm our pre-existing
128

See Alvin Rajkomar et al., supra note 29; see also Muhammad Aurangzeb Ahmad et al.,
Fairness in Machine Learning for Healthcare, KDD ’20: PROCEEDINGS OF THE 26TH ACM
SIGKDD INTERNATIONAL CONFERENCE ON KNOWLEDGE DISCOVERY & DATA MINING 3259
(August 2020) (“Even outside of AI/ML, healthcare and medicine have a long history of implicit
or explicit bias which has been well documented: There is a large body of research showing that
minority patients receive poorer quality of care despite similar disease severity, clinical
presentation and medical insurance. Healthcare has been rife with examples of algorithmic
discrimination.”).
129
See, e.g., Natasha Lomas, DeepMind touts predictive healthcare AI ‘breakthrough’ trained on
heavily skewed data, TECHCRUNCH (July 31, 2019), https://techcrunch.com/2019/07/31/deepmindtouts-predictive-healthcare-ai-breakthrough-trained-on-heavily-skewed-data/ (discussing how
Google’s AI model predicting likelihood of kidney injury produced heavily flawed results which
excluded specific demographic groups); Ziad Obermeyer et al., Dissecting Racial Bias in an
Algorithm Used to Manage the Health of Populations, 366 SCIENCE 447 (2019) (evaluating a
specific health care algorithm which disproportionately favored distributing limited resources to
white patients because their average cost of care was higher than a black patient’s).
130
Hoffman & Podgurski, supra note 115, at 6 (noting that algorithmic discrimination may violate
sections of both the Civil Rights Act and the Affordable Care Act).
131
See, e.g., Spitzer, supra note 12 (discussing Watson’s mistaken recommendation of
inappropriate treatments for cancer patients).
132
See Ben Dickson, Healthcare Algorithms Are Biased, and the Results can be Deadly, PC MAG
(Jan. 23, 2020), https://www.pcmag.com/opinions/healthcare-algorithms-are-biased-and-theresults-can-be-deadly.
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See Eliane Röösli et al., Bias at warp speed: how AI may contribute to the disparities gap in the
time of COVID-19, 28 J. AM. MED. INFORMATICS ASSOC. 190, 191 (2020) (arguing that AI models
used in allocation of limited-availability ICU beds for COVID-19 patients may improperly
allocate those beds based on biased data about comorbidity).
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biases.”134 Biased algorithms exist everywhere: two notable examples of visibly
biased output from algorithms are 1) Amazon’s employment algorithm, which
unfairly disqualified women as candidates for high-ranking positions at the
company;135 and 2) Google DeepMind’s predictor of kidney injury,136 which
despite its claim of high success, had not been trained on adequate data for
women or minorities.137
While not a health-related example, the Amazon situation was noteworthy
due to the glaring employment discrimination that resulted from its use of biased
AI. Amazon had been running algorithms for the purpose of recruiting “top
talent.”138 The algorithms gave job candidates a ranking of one to five stars, much
like Amazon’s virtual catalog of goods.139 The ranking was based on the
similarities between candidates’ résumés and patterns observed in résumés
submitted over the course of ten years.140 The patterns were predominantly
learned from men’s résumés, since men held most of the positions in the
company; thus, the system taught itself that résumés with the word “women’s”
were less desirable than others.141 The technology also favored descriptive words
more commonly found on male engineers’ résumés, such as “executed” or
“captured.”142
The second example, Google DeepMind, came as a surprise after the
company had touted its ability to correctly predict “90 percent of acute kidney
injuries that would end up requiring dialysis.”143 What Google failed to announce
was that its breakthrough was built on data that skewed 93.6% male;144
additionally, only 18.9% of patients were Black, and no other ethnicities were
134

See Dhruv Khullar, A.I. Could Worsen Health Disparities, N.Y. TIMES (Jan. 31, 2019),
https://www.nytimes.com/2019/01/31/opinion/ai-bias-healthcare.html.
135
Jeffrey Dastin, Amazon Scraps Secret AI Recruiting Tool that Showed Bias Against Women,
REUTERS (Oct. 10, 2018), https://www.reuters.com/article/us-amazon-com-jobs-automationinsight/amazon-scraps-secret-ai-recruiting-tool-that-showed-bias-against-womenidUSKCN1MK08G.
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Lomas, supra note 129.
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Id.
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Dastin, supra note 135.
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Id.
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Id.
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Id.
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Id.
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Christina Farr, Google’s DeepMind says its A.I. tech can spot acute kidney disease 48 hours
before doctors spot it, CNBC (Jul. 31, 2019), https://www.cnbc.com/2019/07/31/googlesdeepmind-says-its-ai-sees-acute-kidney-disease-48-hours-early.html.
144
Lomas, supra note 129. Lomas notes that DeepMind’s AI was trained using patient data from
the U.S. Department of Veteran Affairs, which skews heavily male and white.
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designated in the results data.145 The predictive capability may be valuable, but it
remains untested on a more representative population.
One area of major concern is in clinical trial data: most clinical trials take
place in Europe and the United States,146 and middle-class white males are
overrepresented in those trials.147 This is problematic in that new treatments and
therapies are often not tested on a representative group of would-be patients, and
thus the un- or underrepresented groups have no data indicating whether a
proposed treatment would be effective (or cause harm).148 Datasets compiled from
clinical trials in general require significant curation and correction to avoid
inaccuracies leading to biased algorithmic output.149
A recent and ongoing concern is that AI bias may have worsened or will
continue to worsen inequalities for people of color in terms of response to
COVID-19.150 Use of unrepresentative data samples to predict the effect and
severity of COVID-19,151 where the data has been independently collected by
separate entities and does not include representative data for minority groups, may
lead to non-optimal allocation of vital resources to those groups.152 People of
color may thus be less likely to receive life-saving treatment when presenting with
COVID symptoms. The reason for these disparities is simple, but difficult to
remedy without acknowledging and correcting disparities in healthcare treatment:
available training data is mostly “white and male.”153
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https://medicalfuturist.com/a-i-bias-in-healthcare/ (discussing the disparities in source, quality,
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c.

The Question of Transparency and Explainability

Previous administrations, and Congress itself, have noted the bias and
disparity issues inherent in AI, and one common aspect of their proposed
responses is a requirement for increased transparency into algorithmic
processes.154 However, there is a sizable gap between traditional notions of
transparency and what is realistic or feasible for insight into AI. Software
transparency refers to visibility of the actual code being used when a program is
running. ML processes learn from data and solve problems dynamically.155 After
an ML algorithm has been developed, tested, and pushed to market in any form, it
is normally “black boxed”156—that is, it is programmed such that its input and
output is visible without giving the user any knowledge of the internal workings
of the algorithm.157 An end user (a hospital, doctor’s office, patient, or research
facility) would therefore have no visibility into that algorithm’s operation.
This lack of transparency has understandably been a pivotal concern for
lawmakers.158 However, the solution to black boxing is not simple. “Whiteboxing” code159 very likely infringes on the intellectual property rights of the
company that wrote the algorithm.160 In addition, white-boxing code may be an
inadequate method of governing algorithmic solutions.161 Because ML algorithms
are constantly learning, an engineer who designed an ML system may not be able
154

This was referenced in the most comprehensive piece of attempted legislation, the Algorithmic
Accountability Act of 2019. In the case of the Act, the “transparency” requirement included a
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(last visited Nov. 1, 2020).
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See Frank A. DeCosta, III & Aliza G. Carrano, Intellectual Property Protection for Artificial
Intelligence, FINNEGAN (Aug. 30, 2017)
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to precisely say where a problem is occurring even with total visibility.162 Some
aspects of algorithmic calculations “never take durable, observable forms.”163
This has been referred to as the “transparency paradox”: more data does not mean
more information.164
The lack of comprehensibility would strongly favor an “explainability”
model. In this model, a developer or company would provide an explanation of a
code’s process– in plain language– to an end user rather than opening the code for
viewing.165 The explainability model is favored by NIST,166 which states that
“explainable AI is a key element of trustworthy AI.”167 Explainability should be
contextual: some audiences will require “global” (entire) explanations while
others will need “local” explanations (specific to one algorithmic decision).168
This approach is preferable to traditional white-boxing in most contexts. The
Harvard Data Science Review has promulgated an alternative, but similar,
approach: “interpretable” models using simpler, more intelligible algorithms.169
Wider-spread development of interpretable AI would provide an alternative to
both black-boxing and the need to have developers, or companies, fully explain an
algorithm.
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Id. at 981.
164
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IV.

Current Attempts to Manage the Medical Matrix
a.

Navigating the Regulatory Landscape: the FDA, the
FCC, and the FTC

AI models are woefully under-regulated at every stage of development and
use. Some health-related AI is currently subject to regulation by the FDA, and
other AI may fall under a general purview of the Federal Trade Commission
(FTC) or Federal Communications Commission (FCC). Yet more must be done:
the evolution of AI is swift and dynamic while legislation and rulemaking are
not.171
170

1.

The Self-Limited Role of the FDA

The FDA currently governs medical devices and “Software as a Medical
Device” (“SaMD”).172 The agency is aware that something must change. It has
stated that its “traditional paradigm of medical device regulation was not designed
for adaptive artificial intelligence and machine learning technologies.”173
The obvious answer for regulation of all health-focused AI would be FDA
oversight, but the obvious answer is not always the correct one. Although some
AI is subject to FDA oversight, the broader regulatory framework “is yet to be
developed.”174 The U.S. Government Accountability Office’s report on AI in
health care dated December 2019 summarizes stakeholders’ concerns that there is

170

See Nicolas Terry, Of Regulating Healthcare AI and Robots, 18 YALE J. HEALTH POL’Y, L. &
ETHICS 133 (2019).
171
Id. at 150 (“[A] real question arises as to whether the FDA can keep up with the rapid
innovations in digital health and, particularly, in healthcare AI”).
172
Examples of SaMD include: software that allows a smartphone to view MRI imaging, software
intended for diagnosis of a specific medical condition; and computer-aided detection software that
performs image post-processing to help detect breast cancer. See What are examples of Software
as a Medical Device?, FDA (Dec. 6, 2017), https://www.fda.gov/medical-devices/softwaremedical-device-samd/what-are-examples-software-medical-device.
173
Artificial Intelligence and Machine Learning in Software as a Medical Device, FDA (Sept. 22,
2021), https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligenceand-machine-learning-software-medical-device#regulation [hereinafter FDA AI/ML].
174
See Kavita Sharma and Padmavati Manchikanti, Regulation of Artificial Intelligence in Drug
Discovery and Health Care, 39 BIOTECHNOLOGY L. REP. 371 (2020) (“While there are a good
number of AI-based applications being developed, some being approved for commercialization
and use by United States Food and Drug Administration (FDA) in the health care sector, the
regulatory framework is yet to be developed.”).

131

Journal of Law, Technology & the Internet – Vol. 13

“not enough guidance about what information or data FDA will require for
approval of machine learning uses.”175
Indeed, the FDA has been grappling with regulation of health technology
for years. It was given authority to regulate medical devices as far back as
1976,176 which later expanded to SaMD.177 In 2016, the definition of “medical
device” was altered under the 21st Century Cures Act.178 Under the new
definition, the FDA “will not regulate software that uses ‘big data’ to provide
clinical decision support,”179 with an exception for situations where it “would be
reasonably likely to have serious adverse health consequences.”180 On top of the
changes made by the 21st Century Cures Act, as of 2020, the FDA had only
approved device-based, higher-risk, health-focused AI with “locked”
algorithms.181 The agency does not intend to regulate lower-risk software, out of a
desire not to hinder development.182
In 2019, the FDA proposed an “innovative framework” for AI which
considered a “total product lifecycle.”183 The total product lifecycle would
involve an approach in which the FDA “would expect a commitment from
manufacturers on transparency and real-world performance monitoring . . . as well
as periodic updates to the FDA on what changes were implemented.”184 Still, this
does little in terms of regulatory action—it is more of a notice requirement, and it
includes the arguably flawed obligation of transparency. In January of 2021, the
agency published an action plan to update its policies on AI/ML devices and
175
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SaMD.185 The plan outlines five components that the agency plans to implement,
including: 1) a tailored regulatory framework; 2) good machine learning practice
(“GMLP”); 3) a patient-centered approach incorporating transparency; 4) use of
regulatory science methods related to bias and robustness; and 5) “real-world
performance” metrics.186
Although the 2021 plan specifically mentions the need to improve
methodologies for identifying bias in ML, it does not address the larger issue of
poorly-sourced and poorly-tested datasets in health-focused AI outside of
SaMD.187 It also does not speak to the rapidly-changing nature of AI devices or
models in health technology.188 Further, it echoes the “transparency” language
found in other government proposals, language which would be better stated as
“explainability,” or even, following the Harvard Data Science Review’s
argument, “interpretability.”189 The plan does, however, speak to standardization
via the GMLP step.190
2.

Traversing the Health/Wellness Terrain: the FCC
and FTC

A remaining issue lies in the narrowing gap between health and wellness
devices. Commonly used “wellness” physical technologies include wearable
fitness trackers and at-home “Internet of Things” tools such as smart scales,
technologies which are subject to a variety of regulatory schemes and agencies.191
185

U.S. FOOD & DRUG ADMINISTRATION, ARTIFICIAL INTELLIGENCE/MACHINE LEARNING
(AI/ML)-BASED SOFTWARE AS A MEDICAL DEVICE (SAMD) ACTION PLAN, FDA.GOV (Jan. 2021),
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188
See Andrej Kovacevic, AI Moving into Healthcare, Regulatory Challenges Await, READWRITE
(Mar. 13, 2020), https://readwrite.com/2020/03/13/ai-moving-into-healthcare-regulatorychallenges-await/ (“[T]he capabilities, safety, and efficacy of some of the newest medical AI
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can undergo thorough testing and gain approval, an AI’s performance may be different the day
after its undergone testing. What’s more, there’s no telling if the performance differences will
make it work better or worse. That’s why regulators like the US’s Food and Drug Administration
(FDA) have thus far only started to approve locked-algorithm solutions.”).
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See Gicel Tomimbang, Wearables: Where do they fall within the regulatory landscape?, IAPP
(Jan. 22, 2018), https://iapp.org/news/a/wearables-where-do-they-fall-within-the-regulatorylandscape/; Charlotte A. Tscheider, Regulating the Internet of Things: Discrimination, Privacy,
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Many wellness-based physical home devices fall under separate regulatory
structures outside the scope of the FDA.192 Thus, a significant question in
oversight is which agency, if any, has authority over a specific type of healthrelated AI. The answer is not always clear. Companies that produce devices walk
a line—one that is blurring193—between creating health devices (which are
regulated by the FDA via the Food, Drug, & Cosmetic Act)194 and wellness
technologies (which are not).195 This gap in oversight largely exists because
current regulatory agencies only regulate the technologies that fall specifically
within their preordained domain. In the case of the FDA, those technologies are
medical devices and SaMD.
Wellness devices may be subject to scrutiny and oversight that has nothing
to do with health care data, at least not directly. The FCC governs devices that
emit a radio or Bluetooth signal,196 while the FTC oversees truth-in-advertising
issues for health-based services or devices.197 The FTC also acts as the “default
regulator” of privacy and security issues.198 Yet devices that only fall under these
limited regulations may still be running predictive algorithms, learning personal
health data, and creating valuable databases of (non-medical) information. Of
additional concern to the health industry is that if a health-focused software
192

See Tschider, supra note 191, at 123.
See generally Lauren Horwitz, Line Between Consumer Wellness and Traditional Medicine
Blurs Further, IOT WORLD TODAY (Jan. 28, 2020),
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company’s work falls outside the scope of the FDA because it uses adaptive,
dynamic algorithms,199 that company’s data standards may not currently be
regulated.200
b.

If Not the FDA, Who?: Former Executive Orders and
Policymaking

It is clear to the author that AI requires regulation, and that regulation
needs to be “unitary, not fragmented.”201 That unity cannot exist without
centralized standardization. Both the Obama administration and the Trump
administration acknowledged the importance of AI,202 and President Trump
released two Executive Orders on the subject.203 The Biden administration will
likely start regulating in a manner akin to EU.204 Several pre-existing initiatives
are already in place, including creating a new National AI Initiative Office.205
199

The FDA currently only regulates locked, device-based algorithms in health care, which can
include algorithms that manage a physical medical device or algorithms that perform a specific,
non-adaptive health-related function. See generally Benjamens et al., supra note 46.
200
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system can change as it learns, existing regulation does not effectively manage potential risks and
a new approach is required.”).
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ADMINISTRATION), https://trumpwhitehouse.archives.gov/ai/ (last visited Apr. 19, 2022).
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President Trump’s order of 2019, the Executive Order titled “Maintaining
American Leadership in Artificial Intelligence,”206 signaled the growing and
thriving role of AI throughout the U.S. economy and worldwide. It called for an
interagency approach to the development and regulation of AI.207 That approach
was to be spearheaded by the National Science and Technology Council.208 It
would have involved a staggering number of agencies, including the National
Security Foundation, National Institutes of Health, U.S. Department of Energy,
and the Intelligence Advanced Research Projects Activity board.209 This was
notable because the Trump White House presented another interagency-themed
approach towards the end of his presidency in 2020, signaling the continued
prevailing belief that this issue needs to be addressed by experts in multiple
fields.210
A later document, a memorandum released by the White House Office of
Management and Budget (OMB) in November 2020, offered guidance for the
regulation of AI.211 The guidance was based upon the NIST AI standards, which
are a work in progress.212 It provided a broad set of principles for managing AI
through interagency regulatory and non-regulatory methods. Those methods
would be overseen by the Office of Information and Regulatory Affairs
(OIRA).213 This guidance was meant to be a comprehensive, final statement on
how the federal government will be approaching AI.
However, the OMB memorandum misses the mark in several ways. The
memorandum strongly favored a hands-off approach: the OMB indicated that
federal agencies “must avoid regulatory or non-regulatory actions that needlessly
hamper AI innovation and growth.”214 This would continue, if not exacerbate, the
existing problem of “wild west” data. The memorandum stressed fairness, non2021, BROOKINGS (Jan. 21, 2021), https://www.brookings.edu/research/6-developments-that-willdefine-ai-governance-in-2021/.
206
Maintaining Leadership, supra note 203.
207
See Maintaining Leadership, supra note 203.
208
Id.
209
Felten & Lyons, supra note 202.
210
Memorandum from the Executive Office of the President to the Heads of Executive
Departments and Agencies (Nov. 17, 2020),
https://www.whitehouse.gov/wpcontent/uploads/2020/11/M-21-06.pdf [hereinafter OMB
Memorandum on AI].
211
Id.
212
See NIST AI STANDARDS, supra note 34.
213
OMB Memorandum on AI, supra note 210, at 10.
214
OMB Memorandum on AI, supra note 210, at 2.

136

Managing the Medical Matrix:A “DAIS” for Artificial Intelligence in Health Care (and
Beyond)

discrimination, disclosure, and transparency215 and required agencies to adopt
common (NIST) standards,216 which are admirable guidelines, but challenging if
not impossible to enforce. It placed a high hurdle to clear before OIRA would
approve any rulemaking,217 effectively tying the hands of the agencies involved.
The NIST standards are too loose to be adequately implemented, as they
are non-specific and intended to be frameworks rather than enforceable
regulations.218 Additionally, OIRA may not have the ability to adequately manage
regulatory oversight: OIRA has a relatively small staff and likely lacks the
required AI expertise to suggest or approve AI regulations, not to mention that
OIRA’s role is primarily reactive rather than proactive.219 Lastly, “transparency,”
as mentioned in the document, is too broadly defined to be of practical use, a
common problem in proposals relating to AI management.220 The OMB
memorandum is wholly insufficient in areas like health care that require stricter,
tougher regulation to avoid potentially harmful consequences.221
c.

The Algorithmic Accountability Act of 2019

Numerous attempts at federal legislation involving AI have been made.222
In 2018 alone, thirty-nine bills were introduced that included the words “artificial
intelligence” in the text.223 Each attempt, however, has been met with confusion
215

Id. at ¶¶ 7, 8.
Id. at 10.
217
Id.
218
NIST AI STANDARDS, supra note 34; see also Nate Lord, What is NIST Compliance?,
DATAINSIDER: BLOG (Dec. 1, 2020), https://digitalguardian.com/blog/what-nist-compliance
(“NIST standards are based on best practices from several security documents, organizations, and
publications, and are designed as a framework for federal agencies and programs . . . ”).
219
Id. But see Lisa Schulz Bressman, Flipping the Mission of Regulatory Review, REGULATORY
REV. (Feb. 18, 2021), https://www.theregreview.org/2021/02/18/bressman-flipping-missionregulatory-review/ (discussing President Biden’s suggestion that OIRA be given authority to
develop, rather than review, “regulations that advance the Administration’s values.” It is plausible
that AI would become one of those values if this moved forward.)
220
The OMB Memorandum on AI states: “What constitutes appropriate disclosure and
transparency is context-specific, depending on assessments of potential harms.” OMB
Memorandum on AI, supra note 210, at ¶ 8. This language is so broad that it leaves the assessment
of harm open to total interpretation.
221
Id.
222
AI Legislation Tracker—United States, CTR. FOR DATA INNOVATION,
https://www.datainnovation.org/ai-policy-leadership/ai-legislation-tracker/ (showing ten AI related
bills in 2020, eight in 2019, and three in 2018) (last visited Apr. 19, 2022).
223
James Martin, United States: Federal Legislation and Regulatory Action, in REGULATION OF
ARTIFICIAL INTELLIGENCE IN SELECTED JURISDICTIONS 27, LIBR. OF CONG. (Jan. 2019),
https://www.loc.gov/law/help/artificial-intelligence/regulation-artificial-intelligence.pdf.
216

137

Journal of Law, Technology & the Internet – Vol. 13

and questioning at the Congressional level224 due at least in part to a
misunderstanding of the technologies involved.225 Congress has realized that there
is a need for some form of government action given the observable “racist
impacts” of AI226 and has signaled that it is serious about equity and bias. It made
its farthest-reaching attempt into regulating AI with the Algorithmic
Accountability Act of 2019.227
In 2019, Senators Cory Booker and Ron Wyden, along with
Representative Yvette Clarke, introduced a bill titled the “Algorithmic
Accountability Act” (“the Act”).228 The Act was Congress’ first real foray into
national governance of AI.229 It directed the FTC to make rules that would
regulate “impact assessments” for “high-risk automated decision-making
systems,”230 and would have applied to companies that had over $50 million a
year in average annual gross receipts.231 An impact assessment would have
involved a study evaluating development, design, and training data, but also
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required that all of the above be made publicly available.232 The Act was a wellmeaning but flawed attempt to force private sector entities to closely examine and
audit their AI for bias.233
The Act fell short of covering health industry-related needs in that it only
applied to major companies with large systems234—which may include some
larger hospital systems, but not smaller health offices and health-related
companies.235 The Act was also impractical in that it ignored the reality of
software development and the iterative process.236 Due to the nature of software
development and testing, it would not be feasible to require impact assessments
for every new update that was pushed by the developer or developing company.237
A better option would be to require standardization of sourced data and data input,
as the OMB attempted to do with its memorandum.238
Commendably, the Act did set forth requirements for running an impact
assessment on an automated decision system’s “process,” including its design and
its training data.239 The authors of the Act seemed to recognize that bias could be
inadvertently introduced at the training stage. However, the Act did not directly
provide for the ability to review data sourcing or impose a set of data quality
standards on the creators of the algorithms.
The Act “produced more lessons learned and questions than actionable
law,”240 which its proponents recognized. In December of 2019, Senator Booker
sent letters to the FTC and the Centers for Medicare and Medicaid Services
232
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requesting that they provide information on how they were addressing biases in
health care.241 This at least implies that Congress is seriously considering how to
include health care in future attempts at oversight of AI.
V.

The Final Frontier: Next Steps in Creating Oversight

AI touches every aspect of industry and technological development, and as
such, it absolutely requires oversight. There is strong support for AI regulation in
big tech.242 Professional organizations and policy institutes like the American
Medical Association243 and the Department of Health and Human Services’
Center for Open Data Enterprise, a nonprofit focused on shared data,244 should be
applauded for their efforts in providing a path to responsible AI implementation.
However, several journalists and scholars have expressed disdain for continued
“ethical guidelines” for “trustworthy AI” without regulatory action.245 Even
industry megaliths have called for regulation of AI.246 Google CEO Sundar Pichai
241
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recognized the need for “proactive, sector-by-sector” regulation.247 Ryan
Hagemann of IBM is calling for “co-regulation” with government entities.248 Elon
Musk of Tesla and SpaceX called for increased regulation as far back as 2017.249
Furthermore, Jack Clark of OpenAI “supports the idea of governments taking
increasing responsibility for monitoring and evaluating AI.”250 The industry is
aware of the need, and federal agencies have a basic understanding of the need to
regulate. The solution here is standardization, and standardization can be achieved
via the creation of a new regulatory body.
a.

One Does Not Simply Rewrite the Algorithmic
Accountability Act

As tempting an answer as it might be, the Algorithmic Accountability Act
cannot simply be rewritten to address its original shortcomings. The heart of the
bias problem that the Act intended to address lives in the data itself, far more than
in transparency and public access, which were the focus areas of the Act. Thus, a
second attempt at an Algorithmic Accountability Act is not advisable. Policy
alone is also not the answer: broad policy frameworks can be informative, but are
high-level and often contain ill-defined principles.251 They are not sufficient for
comprehensive management of AI.252 What is required is the creation of a new
regulatory body.
The creation of a new regulatory body may seem to be an extreme
solution; after all, the most recently created entity was the Department of
Homeland Security in 2002 following the terrorist attacks of September 11,
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2001.253 It can be argued, however, that AI and the need to manage it at the
federal level is as important as the need to prevent terrorism (if not more so). AI is
present in all Americans’ everyday lives in some way, shape, or form.254 It is
potentially seriously damaging to both individuals’ and organizations’ finances,
health, privacy, and safety if not properly managed.255 Because of this, a new
agency may be the only logical way to oversee and manage this exciting, but
possibly dangerous, technology.
Any act of Congress would therefore need to detail how to create this new
entity and determine the rulemaking authority it ought to have. This is not the first
proposal calling for a new digital or data-focused agency,256 but it is the only one
(to the author’s knowledge) that is focused solely on AI.
b.

Raising the DAIS (Department of Artificial Intelligence
Standardization)

Regulation is the best answer to the issues presented by AI, as evidenced
by the fact that regulation has already been proposed by Congress and the OMB.
However, neither the FTC (as suggested by Congress)257 nor OIRA (as suggested
by the OMB) would provide sufficient oversight. What is needed is a regulatory
body comprised of experts in technology and software development which
operates at the highest tier and creates rules for data standardization in AI.
253
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The Department of Artificial Intelligence Standardization (DAIS) would
provide authoritative expertise in AI and ML across industries. DAIS would be
responsible for creating and maintaining a shared, mandatory set of rules for data
sourcing and cleaning. Those rules would create a baseline across industries while
providing flexibility for other agencies, like the FDA, to integrate their own future
(or existing) rules around ethical use of AI. DAIS would also create rules around
explainability or intelligibility.258 DAIS would necessarily include a new White
House Cabinet position, since a Presidential advisor would be required in order to
apprise the administration of rulemaking decisions or propositions related to this
extremely important technology.259
DAIS could also be tasked with some of the same goals that the
Algorithmic Accountability Act assigned to the FTC: issuing and enforcing
regulations that require entities using AI to run internal “impact assessments” for
the purpose of identifying bias or security issues.260 DAIS could require use of
clean, cohesive, and representative datasets in training and testing predictive
models by creating compliance rules for technology companies around data
sourcing and cleaning. In addition, DAIS could work with the FDA in a joint
review of EHRs to identify data input needs and regulate use of NLP for data
retrieval.261
An act of Congress creating DAIS would need to include the following
elements. First, Congress must provide that DAIS have overarching authority to
create rules that address standardization of data sourcing across industries—for
example, it might require that testing datasets meet a specific quality threshold,
and that training data be obtained from broad representative sources. Second,
Congress must provide that all other agencies overseeing AI, or which have
regulatory authority over industries that utilize AI, adhere to the DAIS set of
uniform fields when designing AI systems. Third, Congress must provide the
ability for DAIS to collaborate with other regulatory agencies as required to
258
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create, publish, and review supplementary rules specific to those agencies’ served
industries; for example, the “joint review” of EHRs suggested above.262 Fourth,
Congress must provide that DAIS periodically—perhaps annually—revisit,
refresh, and publish updated standards that integrate any new developments in
how AI technologies are built. Fifth, and lastly, Congress must dictate that DAIS
create a uniform method for data cleaning and de-identification.263 DAIS would
itself be comprised of data engineers, experienced technology managers, and an
advisor (Cabinet member) to the President’s office on all matters related to
regulation of AI.
VI.

Conclusion

AI is an extraordinary, exciting, and burgeoning field—one that is broadly
infiltrating health care and all other technology industries and will continue to do
so. Inherent in any rapid and far-reaching developments in technology are
inevitable stumbling blocks, all of which are part of the development process.
However, the stumbling blocks and hazards of health-related AI are not benign.
Real and tangible consequences of poorly sourced training datasets are rooted in a
dearth of standardization. Consequences include inappropriate or deficient
treatment methods, incorrect predictions of disease, and even refusal of lifesaving services. While data standards have been suggested, and although the
health care industry is aware of the dangers involved with use of AI, no method of
mandating those standards or ensuring clean representative data has been
established. The answer does not lie in broad policy frameworks or in oversight
by a non-AI-specific authority. It also should not lie in assigning additional,
unwanted responsibility to an already overtaxed regulatory authority like the
FDA. Instead, a new, AI-specific regulatory body, DAIS, must be established.
Increased regulation may not seem like an ideal solution given the rapid
pace of software development. It is for this reason that I suggest that DAIS be
comprised of data engineers and technical experts who would be responsible for
creating workable data standards that keep pace with the evolving nature of
technology. I further suggest that DAIS could and should collaborate with
industry-specific agencies on creating rules for their needs. This would provide
for deeper, broader oversight of the use of AI in health care while still
encouraging development and discovery. Uniform, enforceable standards would
262
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allow for swifter and more widespread use of high-quality training data, which
would in turn lead us towards truly unbiased AI and far better predictive
capabilities.
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